Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.

Archive ouverte

Pastor, Rebecca | Habersetzer, François | Fafi-Kremer, Samira | Doffoel, Michel | Baumert, Thomas-F | Gut, Jean-Pierre | Stoll-Keller, Françoise | Schvoerer, Evelyne

Edité par CCSD ; Baishideng Publishing Group Co. Limited -

International audience. Anti-hepatitis B virus (HBV) therapy leads to the emergence of mutant viral strains during the treatment of chronic hepatitis B with nucleos(t)ides analogues. The existence of HBV variants with primary antiviral resistance may be important for treatment choice. We studied two patients with chronic HBV infection by sequencing the HBV polymerase gene. They had adefovir- and tenofovir-related mutations in the viral polymerase, although they had never been treated. These mutations were rtV214A/rtN238T in one patient and rtA194T in the other. Thus, mutations in untreated patients deserve cautious surveillance. These data indicate that mutations that can theoretically confer adefovir or tenofovir resistance may emerge in treatment-naive patients.

Consulter en ligne

Suggestions

Du même auteur

Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization

Archive ouverte | Schvoerer, Evelyne | CCSD

International audience

Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks

Archive ouverte | Murray, John | CCSD

International audience. The poor response to the combined antiviral therapy of pegylated alfa-interferon and ribavarin for hepatitis C virus (HCV) infection may be linked to mutations in the viral envelope gene E1E2...

Evaluation of three commercially available hepatitis C virus antibody detection assays under the conditions of a clinical virology laboratory

Archive ouverte | Zachary, Pierre | CCSD

International audience. Most studies evaluating antibody detection assays are conducted on samples from healthy blood donors but not on samples of hospitalized patients which can show non-specific reactions.

Chargement des enrichissements...